Вануцизумаб

C₆₅₂₉H₁₀₀₃₃N₁₇₃₃O₂₀₃₈S₄₆

• Молярная масса: 146887,94 г/моль
• Химическое название: immunoglobulin recombined G1-kappa/lambda, anti-[Homo sapiens ANGPT2 (angiopoietin 2, Ang2)]/anti-Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], humanized monoclonal antibody;
  gamma1 heavy chain anti-ANGPT2 (1-463) [Homo sapiens VH (Homo sapiens IGHV1-2*02 (100.00%) -(IGHD)- IGHJ3*02) [8.8.22] (1-129) -Homo sapiens IGKC*01 R1.4>A (130), T1.3>S (131) (130-236) -IGHG1*01 hingeCH2-CH3-CHS (hinge 6-15 (237-246), CH2 (247-356), CH3 Y5>C (365), T22>S (382), L24>A (384), Y86>V (423) (357-461), CHS (462-463)) (237-463)], (236-213')-disulfide with light chain anti-ANGPT2 (1’-213’) [glutaminyl-prolylglycyl (1’-3’) -Homo sapiens V-LAMBDA (Homo sapiens IGLV3-21*02 (100.00%) -IGLJ1*01) [6.3.11] (4'-108') - linker seryl-seryl (109’-110’) -Homo sapiens IGHG1*01 CH1-hinge (CH1 (111'-208') -hinge (1-5) (209’-213’)]; gamma1 heavy chain anti-VEGFA (1-453) [humanized VH (Homo sapiens IGHV3-23*03 (76.80%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -Homo sapiens IGHG1*01 (CH1 (124- 221), hinge (222-236), CH2 (237-346), CH3 S10>C (360), T22>W (372) (347-451), CHS (452-453)) (124-453)],(226- 214')-disulfide with kappa light chain anti-VEGFA (1’-214’) [humanized V-KAPPA (Homo sapiens IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimer (242-232":245-235":365-360")- trisdisulfide
• Drugbank: DB12317
• CAS: 1448221-05-3
• Структура

Информация о действующем веществе Вануцизумаб предназначена для медицинских и фармацевтических специалистов, исключительно в справочных целях.